{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:47:18Z","timestamp":1777045638640,"version":"3.51.4"},"reference-count":30,"publisher":"Zhejiang University Press","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1631\/jzus.b2200631","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:02:44Z","timestamp":1697536964000},"page":"935-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1\/PD-L1 inhibitors","\u5efa\u7acb\u548c\u9a8c\u8bc1\u975e\u5c0f\u7ec6\u80de\u80ba\u764cPD-1\/PD-L1\u6291\u5236\u5242\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\u7684\u98ce\u9669\u9884\u6d4b\u6a21\u578b"],"prefix":"10.1631","volume":"24","author":[{"given":"Qing","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longfei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-7465","authenticated-orcid":false,"given":"Xinyou","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-3165","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"21","key":"730_CR1","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.3390\/ijerph17217995","volume":"17","author":"T Biswas","year":"2020","unstructured":"Biswas T, Kang KH, Gawdi R, et al., 2020. Using the systemic immune-inflammation index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC). Int J Environ Res Public Health, 17(21):7995. https:\/\/doi.org\/10.3390\/ijerph17217995","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"730_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/09513590.2013.852531","volume":"30","author":"C Castelo-Branco","year":"2014","unstructured":"Castelo-Branco C, Soveral I, 2014. The immune system and aging: a review. Gynecol Endocrinol, 30(1): 16\u201322. https:\/\/doi.org\/10.3109\/09513590.2013.852531","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"730_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al., 2016. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol, 27(4):559\u2013574. https:\/\/doi.org\/10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"issue":"4","key":"730_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","volume":"20","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Chiari R, Ricciuti B, et al., 2019. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer, 20(4):237\u2013247.e1. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.006","journal-title":"Clin Lung Cancer"},{"key":"730_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Bersanelli M, Santini D, et al., 2020. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer, 128:17\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2019.12.031","journal-title":"Eur J Cancer"},{"issue":"3","key":"730_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly LE, Power DG, O\u2019Reilly \u00c1, et al., 2017. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer, 116(3):310\u2013317. https:\/\/doi.org\/10.1038\/bjc.2016.431","journal-title":"Br J Cancer"},{"issue":"12","key":"730_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/sj.ijo.0800741","volume":"22","author":"P Deurenberg","year":"1998","unstructured":"Deurenberg P, Yap M, van Staveren WA, 1998. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes, 22(12):1164\u20131171. https:\/\/doi.org\/10.1038\/sj.ijo.0800741","journal-title":"Int J Obes"},{"issue":"15","key":"730_CR8","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, et al., 2019. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res, 25(15):4592\u20134602. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1538","journal-title":"Clin Cancer Res"},{"issue":"4","key":"730_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/PPO.0000000000000124","volume":"21","author":"HF Dvorak","year":"2015","unstructured":"Dvorak HF, 2015. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J, 21(4):237\u2013243. https:\/\/doi.org\/10.1097\/ppo.0000000000000124","journal-title":"Cancer J"},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","volume":"9","author":"Y Eun","year":"2019","unstructured":"Eun Y, Kim IY, Sun JM, et al., 2019. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep, 9:14039. https:\/\/doi.org\/10.1038\/s41598-019-50574-6","journal-title":"Sci Rep"},{"issue":"10","key":"730_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1631\/jzus.B2200195","volume":"23","author":"ZR Gao","year":"2022","unstructured":"Gao ZR, Ling XY Shi CY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed& Biotechnol), 23(10):823\u2013843. https:\/\/doi.org\/10.1631\/jzus.B2200195","journal-title":"J Zhejiang Univ-Sci B (Biomed& Biotechnol)"},{"issue":"5","key":"730_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/jnci\/87.5.361","volume":"87","author":"MS Georgiadis","year":"1995","unstructured":"Georgiadis MS, Steinberg SM, Hankins LA, et al., 1995. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst, 87(5):361\u2013366. https:\/\/doi.org\/10.1093\/jnci\/87.5.361","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"730_CR13","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, et al., 2014. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res, 20(23):6212\u20136222. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-0442","journal-title":"Clin Cancer Res"},{"issue":"4","key":"730_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ijc.33822","volume":"150","author":"YQ Huang","year":"2022","unstructured":"Huang YQ, Soon YY, Aminkeng F, et al., 2022. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. Int J Cancer, 150(4):636\u2013644. https:\/\/doi.org\/10.1002\/ijc.33822","journal-title":"Int J Cancer"},{"issue":"21","key":"730_CR15","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel III","year":"2018","unstructured":"Kugel CH III, Douglass SM, Webster MR, et al., 2018. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res, 24(21):5347\u20135356. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1116","journal-title":"Clin Cancer Res"},{"key":"730_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, et al., 2017. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol, 8:49. https:\/\/doi.org\/10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"issue":"9","key":"730_CR17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.29847","volume":"138","author":"NL Li","year":"2016","unstructured":"Li NL, 2016. Platelets in cancer metastasis: to help the \u201cvillain\u201d to do evil. Int J Cancer, 138(9):2078\u20132087. https:\/\/doi.org\/10.1002\/ijc.29847","journal-title":"Int J Cancer"},{"key":"730_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","volume":"132","author":"D Maillet","year":"2020","unstructured":"Maillet D, Corbaux P, Stelmes JJ, et al., 2020. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer, 132:61\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.017","journal-title":"Eur J Cancer"},{"issue":"7203","key":"730_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, et al., 2008. Cancer-related inflammation. Nature, 454(7203):436\u2013444. https:\/\/doi.org\/10.1038\/nature07205","journal-title":"Nature"},{"issue":"4","key":"730_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/imt.15.12","volume":"7","author":"A Mirsoian","year":"2015","unstructured":"Mirsoian A, Murphy WJ, 2015. Obesity and cancer immunotherapy toxicity. Immunotherapy, 7(4):319\u2013322. https:\/\/doi.org\/10.2217\/imt.15.12","journal-title":"Immunotherapy"},{"issue":"12","key":"730_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, et al., 2016. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol, 2(12):1607\u20131616. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"issue":"1","key":"730_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","volume":"22","author":"GM O\u2019Kane","year":"2017","unstructured":"O\u2019Kane GM, Labb\u00e9 C, Doherty MK, et al., 2017. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist, 22(1):70\u201380. https:\/\/doi.org\/10.1634\/theoncologist.2016-0164","journal-title":"Oncologist"},{"issue":"4","key":"730_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM, 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4):252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"730_CR24","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1158\/1078-0432.CCR-18-1475","volume":"24","author":"G Pawelec","year":"2018","unstructured":"Pawelec G, 2018. Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma? Clin Cancer Res, 24(21):5193\u20135194. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1475","journal-title":"Clin Cancer Res"},{"issue":"9","key":"730_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","volume":"69","author":"LH Peng","year":"2020","unstructured":"Peng LH, Wang Y, Liu F, et al., 2020. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother, 69(9):1813\u20131822. https:\/\/doi.org\/10.1007\/s00262-020-02585-w","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"730_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al., 2017. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"9","key":"730_CR27","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1111\/1759-7714.13541","volume":"11","author":"P Song","year":"2020","unstructured":"Song P, Zhang DD, Cui XX, et al., 2020. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer, 11(9): 2406\u20132430. https:\/\/doi.org\/10.1111\/1759-7714.13541","journal-title":"Thorac Cancer"},{"issue":"6","key":"730_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","volume":"66","author":"MS von Itzstein","year":"2020","unstructured":"von Itzstein MS, Khan S, Gerber DE, 2020. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem, 66(6):779\u2013793. https:\/\/doi.org\/10.1093\/clinchem\/hvaa081","journal-title":"Clin Chem"},{"key":"730_CR29","doi-asserted-by":"publisher","first-page":"648652","DOI":"10.3389\/fimmu.2021.648652","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Li SB, Qiao SM, et al., 2021. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol, 12:648652. https:\/\/doi.org\/10.3389\/fimmu.2021.648652","journal-title":"Front Immunol"},{"issue":"6","key":"730_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00262-020-02793-4","volume":"70","author":"C Zamora","year":"2021","unstructured":"Zamora C, Riudavets M, Anguera G, et al., 2021. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunol Immunother, 70(6):1691\u20131704. https:\/\/doi.org\/10.1007\/s00262-020-02793-4","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2200631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2200631\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2200631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:03:20Z","timestamp":1697537000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2200631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2200631","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Qing QIU, Chenghao WU, Wenxiao TANG, Longfei JI, Guangwei DAI, Yuzhen GAO, Enguo CHEN, Hanliang JIANG, Xinyou XIE and Jun ZHANG declare that they have no conflicts of interest for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China (No. 2019 Scientific Research Ethics (20190211-55)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}